AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAY 16 - (NewsRx.com & NewsRx.net) --
PowderJect Pharmaceuticals, Plc (PJP) announced April 24, 2001, the first achievement of protective immunity by a DNA vaccine in volunteers who do not respond to current commercial hepatitis B vaccines.
The preliminary data from the small hepatitis B DNA vaccine clinical study were presented at the Fourth Annual Conference on Vaccine Research in Arlington, Virginia, by the clinical investigator, Dr. Gregory A. Poland of the Mayo Clinic. The study is part of PowderJect's major DNA vaccine collaboration with GlaxoSmithKline.
The Phase I study, which is still ongoing and will involve 30 healthy volunteers in total, is designed to evaluate the immunogenicity and reactogenicity (tolerability) of the PowderJect hepatitis B DNA vaccine in those who failed to achieve protection from current commercial vaccines (non-responders) and those whose protection has waned. The preliminary data relate to two groups of non-responders: those who did not attain protective levels of antibodies after one course of vaccination (three doses) and those who failed to achieve protection after two or three courses (six to nine doses).
The 11 volunteers in these two groups have received to ...
Source: HighBeam Research, Vaccine Elicits High Responses In Non-Responders.(Brief Article)